** Shares of biotech firm DiaMedica Therapeutics DMAC.O rise 5.7% to $5.95 premarket

** Co says FDA feedback allows prior rat study of dm199, a lab-made protein therapy, to support U.S. human trial application for preeclampsia if drug exposure is confirmed

** Preeclampsia is a serious pregnancy condition marked by high blood pressure that can harm mother and baby

** DMAC says it will run a new rat study to measure drug levels and the drug's activity to meet the FDA's request

** Says dm199 is also being tested for stroke and fetal growth problems

** It plans to start preeclampsia studies in Canada and UK later this year

** As of last close, stock down ~29% YTD